Still struggling to turn its manufacturing around, Dr. Reddy's is recalling 569,000 store-brand famotidine tablets in the U.S.

Some generics makers are responding to industrywide pricing pressure by bulking up via M&A. Not Novartis.

Dasan E&T was handed an FDA warning letter based on an inspection earlier this year that found numerous testing and manufacturing issues at its plant.

While other companies fret about the impact of Brexit, Japan's Takeda will make another investment in its production operations in the European Union.

South Korean drug manufacturer Firson was slapped with a warning letter and placed on an import alert by the FDA.

WuXi NextCODE has raised $240 million in series B, FDA slapped Celltrion with a long Form 483, Biocon's $275 million insulin plant opened shop.

Pfizer is leaning heavily on Celltrion for biosimilar development and manufacturing, but its South Korean partner has stumbled with an FDA inspection.

Japan's Fujifilm Diosynth Biotechnologies has completed a $9 million expansion project of its cell manufacturing facilities in the U.K.